Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1567-1571

  Símová, Jana ^a   Bubeník, Jan ^a   Bieblová, Jana ^a   Rosalia, Rodney Alexander ^a   Fric, Jan ^a   Reinis, Milan ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

HPV16; MHC class I deficient tumours; Residual tumour disease

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL; ARTICLE; C57BL MOUSE; GENE; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; LUNG TUMOR; MALE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MOUSE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REGULATORY T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION;

ANIMALS; COMBINED MODALITY THERAPY; GENES, MHC CLASS I; HUMAN PAPILLOMAVIRUS 16; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM, RESIDUAL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, REGULATORY;

EID: 33845878411     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1567     Document Type: Article

References (28)

1. Vlk V, Rossner P, Indrova M, Bubenik J and Sobota V: Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int J Cancer 76: 115-119, 1998. (Pubitemid 28164577)
2. Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, Bubenik J and Vonka V: Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol 24: 161-167, 2004.
3. Bubenik J and Simova J: Minimal residual disease as the target for immunotherapy and gene therapy of cancer (Review). Oncol Rep 14: 1377-1380, 2005.
4. Klein G and Klein E: Surveillance against tumors - is it mainly immunological? Immunol Lett 100: 29-33, 2005.
5. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T and Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133, 1999.
6. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
7. + regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res 93: 911-916, 2002.
8. Li J, Hu P, Khawli LA and Epstein AL: Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 63: 8384-8392, 2003. (Pubitemid 37549493)
9. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN and Hodge JW: The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 11: 4533-4544, 2005. (Pubitemid 40825644)
10. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201: 779-791, 2005.
11. Terabe M and Berzofsky JA: Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16: 157-162, 2004.
12. Levitsky HI, Lazenby A, Hayashi RJ and Pardoll DM: In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179: 1215-1224, 1994.
13. Bubenik J and Vonka V: MHC class I status of tumours and design of immunotherapeutic strategies. Immunol Lett 90: 177-178, 2003. (Pubitemid 37548474)
14. Bubenik J: MHC class I down-regulation: tumour escape from immune surveillance? (Review). Int J Oncol 25: 487-491, 2004.
15. Reinis M, Simova J and Bubenik J: Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours. Int J Cancer 118: 1836-1842, 2006.
16. Bubenik J: Animal models for development of therapeutic HPV16 vaccines (Review). Int J Oncol 20: 207-212, 2002.
17. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
18. Smahel M, Síma P, Ludvíková V, Marinov I, Pokorná D and Vonka V: Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21: 1125-1136, 2003.
19. Lowenthal JW, Corthesy P, Tougne C, Lees R, MacDonald HR and Nabholz M: High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal antireceptor antibody PC61. J Immunol 135: 3988-3994, 1985.
20. + T cells. J Immunol 175: 1483-1490, 2005.
21. + T cells in spleens and mesenteric lymph nodes of mice infected with Schistosoma japonicum. Acta Biochim Biophys Sin 38: 299-304, 2006.
22. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM and Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651, 2002.
23. Frazer IH: Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4: 46-54, 2004.
24. Mikyskova R, Bubenik J, Mendoza L, Vonka V, Smahel M, Simova J and Jandlova T: Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin Exp Metastasis 18: 581-587, 2001.
25. Bubenik J, Mikyskova R, Vonka V, Mendoza L, Simova J, Smahel M and Indrova M: Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21: 891-896, 2003. (Pubitemid 36126423)
26. Reinis M, Indrova M, Mendoza L, Mikyskova R, Bieblova J, Bubenik J and Simova J: HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol 25: 1165-1170, 2004.
27. + T regulatory cells. J Immunol 176: 3301-3305, 2006.
28. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-{beta}-dependent manner. J Exp Med 202: 1075-1085, 2005.